tirzepatide surmount-1 trial weight loss non-diabetic for the Maintenance of Body Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Obesity surmount-1 tirzepatide non-diabetic obesity weight

Patients experiencing persistent gastrointestinal side effects that interfere with daily activities or nutritional intake may benefit from extending the duration at each dose level beyond the minimum four weeks before attempting further escalation

It is also directly impacted by insufficient choline intake (a type of B vitamin) and imbalanced gut bacteria

Research shows that up to 2540% of weight lost on GLP-1 medications can come from lean tissue (Nature Medicine, 2023)

Studies show oxidative degradation and peptide aggregation increase beyond this window, reducing bioavailability by 1020% or more depending on storage conditions